Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

被引：856

作者：

Afshar-Oromieh, Ali ^{[1
]}

Zechmann, Christian M. ^{[1
]}

Malcher, Anna ^{[1
]}

Eder, Matthias ^{[2
]}

Eisenhut, Michael ^{[2
]}

Linhart, Heinz G. ^{[3
]}

Holland-Letz, Tim ^{[4
]}

Hadaschik, Boris A. ^{[5
]}

Giesel, Frederik L. ^{[1
]}

Debus, Juergen ^{[6
]}

Haberkorn, Uwe ^{[1
,7
]}

机构：

[1] Univ Heidelberg Hosp, Dept Nucl Med, INF 400, D-69120 Heidelberg, Germany

[2] German Canc Res Ctr, Dept Radiopharmaceut Chem, Heidelberg, Germany

[3] Natl Ctr Tumor Dis NCT DKFZ, INF 581, D-69120 Heidelberg, Germany

[4] German Canc Res Ctr, Dept Biostat, Heidelberg, Germany

[5] Univ Heidelberg Hosp, Dept Urol, Heidelberg, Germany

[6] Univ Heidelberg Hosp, Dept Radiat Oncol, INF 400, D-69120 Heidelberg, Germany

[7] German Canc Res Ctr, Clin Cooperat Unit Nucl Med, Heidelberg, Germany

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷 / 01期

关键词：

Prostate cancer; PET/CT; Positron emission tomography; PSMA; Choline; MEMBRANE ANTIGEN-EXPRESSION; POSITRON-EMISSION-TOMOGRAPHY; F-18-FLUORODEOXYGLUCOSE PET/CT; BIOCHEMICAL RELAPSE; F-18-FLUOROCHOLINE; INHIBITOR; DISEASE; ADENOCARCINOMA; BIOPSY; TARGET;

D O I：

10.1007/s00259-013-2525-5

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Positron emission tomography (PET) with choline tracers has found widespread use for the diagnosis of prostate cancer (PC). However, choline metabolism is not increased in a considerable number of cases, whereas prostate-specific membrane antigen (PSMA) is overexpressed in most PCs. Therefore, a Ga-68-labelled PSMA ligand could be superior to choline tracers by obtaining a high contrast. The aim of this study was to compare such a novel tracer with standard choline-based PET/CT. Thirty-seven patients with biochemical relapse of PC [mean prostate-specific antigen (PSA) 11.1 +/- 24.1 ng/ml, range 0.01-116] were retrospectively analysed after F-18-fluoromethylcholine and Ga-68-PSMA PET/CT within a time window of 30 days. Radiotracer uptake that was visually considered as PC was semi-quantitatively analysed by measuring the maximum standardized uptake values (SUVmax) of the scans acquired 1 h after injection of Ga-68-PSMA complex solution (median 132 MBq, range 59-263 MBq) and F-18-fluoromethylcholine (median 237 MBq, range 114-374 MBq), respectively. In addition, tumour to background ratios were calculated. A total of 78 lesions characteristic for PC were detected in 32 patients using Ga-68-PSMA PET/CT and 56 lesions were detected in 26 patients using choline PET/CT. The higher detection rate in Ga-68-PSMA PET/CT was statistically significant (p = 0.04). In five patients no lesion was found with both methods. All lesions detected by F-18-fluoromethylcholine PET/CT were also seen by Ga-68-PSMA PET/CT. In Ga-68-PSMA PET/CT SUVmax was clearly (> 10 %) higher in 62 of 78 lesions (79.1 %) and the tumour to background ratio was clearly (> 10 %) higher in 74 of 78 lesions (94.9 %) when compared to F-18-fluoromethylcholine PET/CT. Ga-68-PSMA PET/CT can detect lesions characteristic for PC with improved contrast when compared to standard F-18-fluoromethylcholine PET/CT, especially at low PSA levels.

引用

页码：11 / 20

页数：10

共 33 条

[1] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].

Afshar-Oromieh, A. ;

Malcher, A. ;

Eder, M. ;

Eisenhut, M. ;

Linhart, H. G. ;

Hadaschik, B. A. ;

Holland-Letz, T. ;

Giesel, F. L. ;

Kratochwil, C. ;

Haufe, S. ;

Haberkorn, U. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495

[2] [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH [J].

Afshar-Oromieh, A. ;

Haberkorn, U. ;

Eder, M. ;

Eisenhut, M. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (06) :1085-1086

[3]

[Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107

[4] Technology Insight: monoclonal antibody imaging of prostate cancer [J].

Bander, NH .

NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (04) :216-225

[5] Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) [J].

Banerjee, Sangeeta R. ;

Foss, Catherine A. ;

Castanares, Mark ;

Mease, Ronnie C. ;

Byun, Youngjoo ;

Fox, James J. ;

Hilton, John ;

Lupold, Shawn E. ;

Kozikowski, Alan P. ;

Pomper, Martin G. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (15) :4504-4517

[6] Pilot comparison of 18F-fluorocholine and 18F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer [J].

Beauregard, J-M ;

Williams, S. G. ;

DeGrado, T. R. ;

Roselt, P. ;

Hicks, R. J. .

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2010, 54 (04) :325-332

[7]

Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO

[8]

2-S

[9] In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer [J].

Breeuwsma, AJ ;

Pruim, J ;

Jongen, MM ;

Suurmeijer, AJ ;

Vaalburg, W ;

Nijman, RJ ;

de Jong, IJ .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (06) :668-673

[10] Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer [J].

Chondrogiannis, Sotirios ;

Marzola, Maria Cristina ;

Ferretti, Alice ;

Maffione, Anna Margherita ;

Rampin, Lucia ;

Grassetto, Gaia ;

Nanni, Cristina ;

Colletti, Patrick M. ;

Rubello, Domenico .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (09) :1356-1364

← 1 2 3 4 →